Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
615 people get GNOM articles and Market Currents by email alert.
Get email alerts on GNOM »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
Complete Genomics' IPO Meets With Lukewarm ReceptionThe Burrill Report • Sun, Nov 14, 2010 -
Complete Genomics Prices IPO Below RangeSA Editor Abbi Adest • Fri, Nov 12, 2010
To learn more about Seeking Alpha Pro, click here.
-
-
Roche Is Back; Buyout Leak Is UnsurprisingPropThink • Thu, Dec 20, 2012
-
China Biotech In Review: China's BGI Acquires Complete GenomicsChinaBio Today • Sun, Sep 23, 2012 -
-
-
-
-
-
-
Friday Options Briefs: WMT, GNOM, ZNGAInteractive Brokers • Fri, May 25, 2012 -
-
-
-
-
6 Highly Liquid Biotech Stocks With Positive Correlation To VolatilityKapitall • Tue, Jan 31, 2012
-
-
-
Short-Sellers Expect These 14 Biotechs To OutperformKapitall • Thu, Jan 5, 2012
-
-
There are no Transcripts on GNOM.
-
at MarketWatch.com (Nov 26, 2012)
-
GlobeNewswire (Nov 9, 2012)
-
GlobeNewswire (Oct 18, 2012)
-
at MarketWatch.com (Oct 15, 2012)
-
at MarketWatch.com (Sep 17, 2012)
-
GlobeNewswire (Sep 17, 2012)
-
at Fox Business (Aug 31, 2012)
-
GlobeNewswire (Aug 8, 2012)
-
GlobeNewswire (Jul 26, 2012)
-
GlobeNewswire (Jul 24, 2012)
-
GlobeNewswire (Jul 11, 2012)
-
GlobeNewswire (Jun 19, 2012)
-
at MarketWatch.com (Jun 5, 2012)
-
GlobeNewswire (Jun 5, 2012)
-
GlobeNewswire (May 9, 2012)
-
GlobeNewswire (May 7, 2012)
-
GlobeNewswire (May 3, 2012)
-
GlobeNewswire (Mar 29, 2012)
-
at MarketWatch.com (Feb 13, 2012)
GNOM vs. ETF Alternatives
Company Description
Currently, there's no company description for GNOM.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, March 12, 9:51 AM BGI-Shenzhen receives approval from China's State Administration of Foreign Exchange for the company's acquisition of Complete Genomics (GNOM +0.8%). The deal has now obtained all the necessary regulatory authorizations. (PR) Comment! [Healthcare, M&A]
- Monday, December 31, 2012, 1:25 PM Complete Genomics (GNOM +0.3%) says that it and BGI-Shenzhen obtained clearance from the Committee on Foreign Investment in the U.S. regarding itI's proposed acquisition of GNOM late Friday. In addition, BGI also extended its all cash offer to purchase all outstanding shares of GNOM until 12:00am ET on Monday, January 7, 2013. The Offer was previously set to expire at 12:00 am ET on Monday, December 31, 2012. Comment! [Global & FX, Healthcare, M&A]
- Monday, November 26, 2012, 12:09 PM Ilumina (ILMN -3.6%) slips today on a Baird dowgrade to Neutral. Baird says there are near-term M&A risks, specifically citing ILMN's own bid for Complete Genomics (GNOM +0.2%) while chatter resurfaces about Roche (RHHBY.OB) potentially trying to buy ILMN again after falling to reach a deal earlier this year. Comment! [Healthcare, On the Move, M&A]
- Monday, November 26, 2012, 8:57 AM California Judge Elizabeth Laporte agrees to review an earlier decision to invalidate certain claims of an Illumina (ILMN) patent. The ruling is connected to a case in which the company has accused Complete Genomics (GNOM) - which Illumina is trying to buy - of breaching its IP. Comment! [M&A, Healthcare]
- Wednesday, November 21, 2012, 11:33 AM BGI-Shenzhen has again extended the deadline for its tender offer to acquire Complete Genomics (GNOM +1.6%), a move that comes in response to Illumina's (ILMN +0.8%) recently disclosed competing bid earlier this month that was rejected by the life sciences company. BGI's tender offer now expires on December 14. Comment! [Healthcare, M&A, On the Move, Global & FX]
- Wednesday, November 21, 2012, 8:26 AM Complete Genomics (GNOM +2.3%) rejects Illumina's (ILMN) $114M bid despite the $3.30/share offer exceeding a $3.15 agreed proposal from China's BGI-Shenzhen. Illumina's bid is also not dependent on funding, nor is it subject to government approval as a foreign investment. Illumina "cannot comprehend" how GNOM "could rationally come to the conclusion" Illumina's offer is not superior. GNOM's shareholders may well agree. Comment! [M&A, Healthcare]
-
Friday, November 16, 2012, 5:40 PM
After-hours top gainers, as of 5:15 p.m.: GNOM +12.5%. GTAT +5.1%. SWFT +4.6%. KFY +4.5%. STRI +4.5%.
After-hours top losers: KWK -10.4%. REGN -9.7%. BPZ -9.4%. FLO -9.2%. NSM -8.7%. Comment! [On the Move] - Tuesday, November 13, 2012, 12:04 PM Shares of Complete Genomics (GNOM +3.3%) are up today on a report that it received an unsolicited $3.30 per share bid from "Party H" on November 5th. The offer follows an earlier tender offer from BGI-Shenzhen last month. Complete Genomics told Party H the bid didn't "constitute a superior proposal" and would likely not gain anti-trust clearance. Comment! [Healthcare, M&A, Global & FX, On the Move]
-
Monday, September 17, 2012, 9:10 AM
Premarket gainers: IRIS +45%. GNOM +15%. ODP +10%. KTOS +9%. CPRX +9%. TSLA +8%. DVAX +7%. CTIC +6%.
Losers: THLD -23%. Comment! [On the Move] - Monday, September 17, 2012, 6:38 AM Genomics firm BGI-Shenzhen plans to purchase Complete Genomics (GNOM) for $3.15 a share through a tender offer. The deal price marks a 54% premium over Friday's closing price for Complete Genomics. (PR) 1 Comment [M&A, Healthcare]
-
Thursday, July 12, 2012, 9:10 AM
Premarket gainers: GNOM +10%. VHC +7%.
Losers: SVU -36%. INFY -10%. IMGN -6%. NMFC -5%. PGR -5%. Comment! [On the Move] - Thursday, July 12, 2012, 8:53 AM Complete Genomics (GNOM) +9.2% premarket and adding to a surge of 44% yesterday after it announced that its Long Fragment Read (LFR) technology, a new way of mapping DNA, "dramatically improves accuracy...and significantly reduces" the amount required for testing." That should make it more accessible to patients. (PR) Comment! [Healthcare, On the Move]
- Tuesday, June 5, 2012, 3:33 PM Complete Genomics' (GNOM +5.3%) restructuring and postponement of capacity expansion are incremental positives for Illumina (ILMN +1.1%), observes Leerink Swann. The firm says v pricing in the whole human genome sequencing market could stabilize as a result of GNOM' actions. Comment! [Healthcare, On the Move]
- Tuesday, June 5, 2012, 8:56 AM Complete Genomics (GNOM) +9.8% premarket after announcing it's laying off ~20% of its workforce to cut costs and has hired a financial adviser to help it explore strategic options including a possible sale of the company. GNOM says it is delaying expanding its monthly genome capacity until customer demand increases. Comment! [Healthcare, On the Move]
-
Friday, May 25, 2012, 9:05 AM
Premarket gainers: GNOM +20%. FRO +7%.
Losers: DCTH -36%. TLB -27%. GENE -11%. PAY -10%. NYMT -6%. VRML -6%. Comment! [On the Move] - Tuesday, May 8, 2012, 3:57 PM Complete Genomics (GNOM -16%) drops hard after missing on its Q1 late yesterday on wider-than-expected losses. Revenue was down 42% Y/Y, largely due to an unexpected revenue recognition deferral for 200 units previously sold into Q2. Comment! [Healthcare, Earnings, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
Asif Suria
Complete Genomics and BGI-Shenzhen Announce Definitive Agreement to Merge $GNOM http://bit.ly/OSEfLP - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
The Berenstain Bulls
PSTI, NBS, GNOM, and Nuvilex (NVLX) all looking swaggish as of late. http://bit.ly/P32kkI - View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Now, 8 hours after close, GNOM is up in still afterhours, but only 8%. Sounds like a lot of investors are cashing in. Maybe you should too. - View all 0 replies
LATEST REPLIES
-
Michael Bryant
Complete Genomics (GNOM) and its DNA sequencing technology looks good. But Neostem (NBS) and stem cells...no. http://yhoo.it/KSyRFj - View all 6 replies
-
-
The Berenstain Bulls: @Maria: Yeah, I like GNOM as well, currently long a few shares.
-
The Berenstain Bulls
PSTI, NBS, GNOM, and Nuvilex (NVLX) all looking swaggish as of late. http://bit.ly/P32kkI - View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 6 replies
-
John Motyka: Michael: Go to singularityhub.com for free newsletter. Rich source of stem cell news including recent Lancet article plus many others...jdm -
-
- View all 3 replies
-
-
-
- View all 4 replies
-
-
-
- View all 6 replies
-
-